TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03021460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00207350

Intervention type: DEVICE
Group type: OTHER
Intervention: Interstitial Laser Therapy
Description: Device
Study: NCT01317485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage and drainage
Description: \[CLOSED\] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~\*\*\*This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidectomy with primary anastomosis
Description: \[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
Study: NCT00838006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Description: Heart rate variability biofeedback, 3 session plus handheld device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training
Description: Cognitive bias modification training - 3 session plus handheld device
Study: NCT01291966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Study: NCT03986125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness & Expression Therapy
Description: emotion-focused
Study: NCT00838006

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Subjects received iPod without a study app and no additional resilience training
Study: NCT03986125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: meditation training and practice
Study: NCT01267474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: The control group received only three one-hour general sessions on health issues.
Study: NCT03984721

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amyloidosis typing using mass spectrometry-based proteomics
Description: Amyloidosis typing using nanoLC-MS/MS method
Study: NCT00800800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 40 mg, oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, single dose
Study: NCT02098694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy follow-up
Description: Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise.
Study: NCT00984880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
Study: NCT02993055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03076918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXITHERALIGHT PDT
Description: Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aktilite® Galderma
Description: Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
Study: NCT00792701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT03864809

Intervention type: BEHAVIORAL
Intervention: sleep disturbance
Description: we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group

Intervention type: BEHAVIORAL
Intervention: sleep disturbance
Description: we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group

Intervention type: BEHAVIORAL
Intervention: sleep disturbance
Description: we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
Study: NCT03213977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH
Description: R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CEOP90
Description: R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
Study: NCT01214317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plasmapheresis
Description: 3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
Study: NCT01403831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily text messages
Description: 2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
Study: NCT02528968

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Package
Description: Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
Study: NCT03404271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-hydroxy beta-methylbutyrate
Description: 3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Performing supervised resistance training three times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Performing supervised resistance training three times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Performing supervised resistance training three times per week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein Supplementation
Description: Consuming a protein supplement daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: Consuming a protein supplement daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: Consuming a protein supplement daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: Consuming all calories within a specified 8-hour period of time each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: Consuming all calories within a specified 8-hour period of time each day.
Study: NCT02227303

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle modification instructional and motivational sessions
Study: NCT03118011

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No smoking
Description: No smoking

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smoking
Description: Ability to go out to smoke
Study: NCT03495453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS
Description: Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device
Description: HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
Study: NCT01718626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1+Docetaxel
Description: Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1+Docetaxel followed by S1
Description: Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
Study: NCT00553553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulphate
Description: Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride, remifentanil hydrochloride
Description: Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure
Study: NCT01790009

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich drink

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 2x500 mg Acetaminophen
Study: NCT03944070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
Study: NCT03636568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Restricted Group
Description: Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients \< 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients \>100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh \> 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~1. Serum Na level must be \< 145 mEq/l~2. Patient should be taking fluids by mouth~3. Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated.
Study: NCT02356146

Intervention type: DRUG
Intervention: Tacrolimus C12
Study: NCT04603040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.
Study: NCT03494426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency thoracic sympathectomy
Description: Under fluoroscopic guidance thoracic sympathectomy will be done as follow~1. antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~2. oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~3. the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin ,tramadol,and tricyclic antidepressants
Description: patient will receive anti neuropathic medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin ,tramadol,and tricyclic antidepressants
Description: patient will receive anti neuropathic medications
Study: NCT02012881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Physical activity during recess, in academic subjects, active transportation and PA home work
Study: NCT01213082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24GyE proton and Anti-VEGF
Description: 24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16GyE and anti-VEGF
Description: 16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Irradiation and anti-VEGF
Description: 2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
Study: NCT01627691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: * bioprosthetic bovine pericardial aortic valve~* delivery system
Study: NCT00253916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic cardiovascular exercise program
Description: Aerobic cardiovascular exercise program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Program
Description: Resistance Exercise Program
Study: NCT01244711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
Study: NCT02012881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: Normal curriculum
Study: NCT00847756

Intervention type: OTHER
Intervention: questionnaire
Description: Identification of risk factors

Intervention type: OTHER
Intervention: questionnaire
Description: Identification of risk factors

Intervention type: PROCEDURE
Intervention: blood sample
Description: venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.

Intervention type: PROCEDURE
Intervention: blood sample
Description: venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
Study: NCT01342731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
Study: NCT02808429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 25 mg
Description: Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
Study: NCT00847756

Intervention type: PROCEDURE
Intervention: collection of middle ear fluid
Description: During routine surgery middle ear fluids are collected per patient.
Study: NCT01103622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral tablet od on Day 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Digoxin
Description: Oral tablet od on Day 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet bd, step-wise increased dosage
Study: NCT04473521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational denture adhesive cream
Description: The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational denture adhesive cream
Description: The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Super Poligrip Free
Description: The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
Study: NCT02808429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
Study: NCT00666848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enalapril 5mg
Description: Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enalapril 10mg
Description: Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
Study: NCT03667014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab treatment
Study: NCT01796158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cASBI+cMET
Description: In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cASBI
Description: In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
Study: NCT04278703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients will be given a prescription for 15 opioid tablets for post-operative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients will be given a prescription for 25 opioid tablets for post-operative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: Patients will be given a prescription for 35 opioid tablets for post-operative pain
Study: NCT04419545

Intervention type: DIAGNOSTIC_TEST
Intervention: Neural network diagnosis algorithm
Description: we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia

Intervention type: DIAGNOSTIC_TEST
Intervention: Neural network diagnosis algorithm
Description: we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
Study: NCT01642550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo